Advertisement
New Zealand markets close in 3 hours 21 minutes
  • NZX 50

    11,878.62
    -67.81 (-0.57%)
     
  • NZD/USD

    0.5967
    +0.0017 (+0.29%)
     
  • NZD/EUR

    0.5560
    +0.0020 (+0.35%)
     
  • ALL ORDS

    7,851.20
    -86.30 (-1.09%)
     
  • ASX 200

    7,590.40
    -92.60 (-1.21%)
     
  • OIL

    83.77
    +0.20 (+0.24%)
     
  • GOLD

    2,340.70
    -1.80 (-0.08%)
     
  • NASDAQ

    17,430.50
    -96.30 (-0.55%)
     
  • FTSE

    8,078.86
    +38.48 (+0.48%)
     
  • Dow Jones

    38,085.80
    -375.12 (-0.98%)
     
  • DAX

    17,917.28
    -171.42 (-0.95%)
     
  • Hang Seng

    17,336.20
    +51.66 (+0.30%)
     
  • NIKKEI 225

    37,670.20
    +41.72 (+0.11%)
     
  • NZD/JPY

    92.8260
    +0.3300 (+0.36%)
     

Analysts See 46% – 49% Upside In Micron But Are Cautious - Read Why

  • Keybanc analyst John Vinh reiterated Micron Technology Inc (NASDAQ: MU) with an Overweight and lowered the price target from $120 to $110, indicating a 48.6% upside.

  • Goldman Sachs analyst Toshiya Hari expects Micron's Q4 revenue and EPS to "land within the company's guided range."

  • However, Hari also notes that recent industry conversations point to a potential downside to his published estimates for Q1 due to soft pricing in DRAM and, to a lesser extent, in NAND.

  • Near-term weakness, particularly in the PC end market, combined with the company's possible decision to re-build inventory and its "tendency to guide conservatively," could lead to a "muted" outlook for Q1, warns Hari.

  • He maintained a Buy rating and $108 price target, implying a 46% upside.

  • Price Action: MU shares traded lower by 1% at $73.3 in the premarket session on the last check Friday.

Latest Ratings for MU

Sep 2021

Mizuho

Maintains

Buy

Sep 2021

JP Morgan

Maintains

Overweight

Sep 2021

Keybanc

Maintains

Overweight

View More Analyst Ratings for MU
View the Latest Analyst Ratings

ADVERTISEMENT

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.